The main purpose of this legislation, known as "Leo's Law," is to address the negative impact of the COVID-19 pandemic on the development of orphan drugs. Orphan drugs are medications designed to treat rare diseases or conditions. The law aims to extend certain exclusivity periods that incentivize pharmaceutical companies to invest in the development of these drugs, ensuring that the progress in this area is not hindered by the pandemic. The key provisions of the law include extending various exclusivity periods for covered orphan drugs by 180 days.